Analysis of Domestic Purchasing Methods and Channels of Jisandai (Bingtongsha)

Epclusa, also known as Epclusa, is an effective treatment for chronic hepatitis C (hepatitis C, caused by HCV infection). If hepatitis C is not treated in time, it may cause serious damage to liver function and even lead to cirrhosis and liver cancer. Gilead Sciences (Bingtonsa) was developed by the American Gilead Sciences company and is an oral drug.

For domestic patients, Jisandai (Bingtonsha) has been officially launched and included in medical insurance, making the purchase very convenient. Its market price remains at around two to three thousand yuan. However, the specific costs and details of medical insurance reimbursement need to be determined according to the policy of the hospital or pharmacy where the patient is located. It is recommended to consult directly to obtain the most accurate information.

In addition, the price of foreign generic drugs of Jisanda (Bingtonsa), especially those produced in Bangladesh and India, is relatively low, ranging from a few hundred to more than a thousand yuan. The main ingredients of these generic drugs are basically the same as those of domestic original drugs.

The remarkable effect of Jisandai (Bingtonsa) is due to the combination of its main ingredients sofosbuvir and vicatatin. Sofosbuvir, as a nucleoside reverse transcriptase inhibitor, can effectively block the synthesis of viral RNA. Vikastatin, as an inhibitor of NS5A, interferes with the key infection steps of the virus. This makes Jisandai (Bingtonsha) have excellent therapeutic effects on various HCV genotypes.

Compared with traditional hepatitis C treatment methods, Jisandai (Bingtonsha) is not only convenient to take orally, but also has a short treatment course (usually 12 weeks) and a high cure rate. Even patients who have failed previous treatments have a good response. At the same time, it has relatively few side effects and is more easily accepted by patients.